Makers Laboratories

Makers Laboratories Current Assets

The Current Assets of Makers Laboratories (506919.BO) as of Oct 18, 2026 is 545.34 M INR. In the previous year, Current Assets was 393.17 M INR — a change of 38.70% (higher).

Current Assets

545.34 MINR

YoY

38.70%

Last updated:

Current Assets of Makers Laboratories is 2026 545.34 M INR. Current Assets of Makers Laboratories was 2025 393.17 M INR. It decreases by 38.70% higher compared to the previous year.

The Makers Laboratories Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2019
227.11 M INR
Jan 1, 2020
236.81 M INR
Jan 1, 2021
608.86 M INR
Jan 1, 2022
626.34 M INR
Jan 1, 2023
629.83 M INR
Jan 1, 2024
440.70 M INR
Jan 1, 2025
393.17 M INR
Jan 1, 2026
545.34 M INR
The Makers Laboratories Current Assets history
YEARCurrent AssetsYoY
545.34 MINR+38.70%
393.17 MINR-10.79%
440.70 MINR-30.03%
629.83 MINR+0.56%
626.34 MINR+2.87%
608.86 MINR+157.11%
236.81 MINR+4.27%
227.11 MINR-17.85%
276.45 MINR+10.58%
249.99 MINR+10.53%
226.17 MINR+3.22%
219.12 MINR-6.93%
235.44 MINR+9.50%
215.00 MINR+13.16%
190.00 MINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Makers Laboratories Stock analysis

What does Makers Laboratories do? Makers Laboratories Ltd is a pharmaceutical company headquartered in Mumbai, India, operating within the Health Care sector. The company has a workforce of 121 employees and went public on July 13, 1993. It manufactures and markets pharmaceutical products, focusing on various therapeutic segments. The company's product portfolio includes formulation brands such as Duramol (Paracetamol), Artemak-AB, Loroquin (Chloroquine), Nimuwin (Nimuselide), Coffwin (anti-cough range), and Exylin (Amoxycillin range). Additionally, Makers Laboratories offers Inspira retail packs, covering categories like acid regulatory, anthelmintics, anti-allergic, anti-asthmatic, anti-biotics, anti-diabetics, anti-diarrheal, anti-emetics, anti-nauseants, anti-fungal, anti-hypertensives, and other health-related products. The Experia bulk packs division provides bulk pharmaceutical products including amoxycillin 250 mg capsules, betamethasone 0.5 mg tablets, cetirizine HCL 10 mg tablets, chloramphenicol capsules 250 mg, chloroquine phosphate 250 mg tablets, chlorpheniramine maleate 4 mg tablets, ciprofloxacin hydrochloride 250 mg tablets, and similar items. The company's website is https://www.makerslabs.com/. Makers Laboratories Ltd is listed on the Bombay Stock Exchange under the ticker 506919.BO and holds the ISIN INE987A01010. The company operates through the pharmaceuticals segment, emphasizing general health therapeutic areas. It does not disclose specific financial figures or additional details beyond its product lines and operational structure. Makers Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Makers Laboratories stock

Current Assets of Makers Laboratories is 545.34 M INR in 2026.

Current Assets of Makers Laboratories changed from 393.17 M INR to 545.34 M INR, representing a 38.70% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Makers Laboratories since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Makers Laboratories historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Makers Laboratories

All Key Metrics — Makers Laboratories